In the Spotlight: James Wade.
Get to know our analyst team one at a time in our new exclusive interviews
James Wade initially joined Datamonitor Healthcare as an Analyst in 2010, and is now our Lead Analyst for our pharma company analysis. James also plays a vital role in developing new platforms to allow our clients to interact with our data in a more visual way. We have put James “In the Spotlight” to find out what he likes about working for us, and what he’s excited for in 2015…
What is your background?
I studied at the University of Bristol where I achieved a first class honours in Neuroscience. I then made the decision to move toward the commercial side of the pharmaceutical industry. After initially working for a clinical research organisation, I moved to Datamonitor in 2010.
What is your role here at Datamonitor Healthcare?
I’m the Lead Analyst of pharma company analysis. I manage and work on our company portfolio, which provides analysis of the leading pharmaceutical companies. We mainly focus on forecasting, strategic analysis and portfolio dynamics. We also look at the bigger picture, so analysing trends across companies, for example big pharma, M&A and so on. Prior to my current role I was a Senior Oncology Analyst.
Within these areas, what has been your most interesting research project?
I have recently been redeveloping and building the new PVX 2.0 (company analysis platform) and content across the portfolio. We want to provide clients with innovative and new analysis that answers key questions quickly, efficiently, and in as much detail as possible. The new tool is really the next generation for our company analysis and the foundation for further development and evolution of the service.
From a drug point of view, I wrote a piece of analysis on oncology personalised therapies and biomarkers. This is still a really interesting and hot topic in oncology with an increasing number of products entering the market. Although development has been heavily weighted toward oncology it is expanding into other disease areas and it seems to be the direction the therapeutic market is moving.
What do you like most about working at Datamonitor Healthcare?
I enjoy being able to provide analysis, insight, and answer key questions around the pharmaceutical industry. The industry is fast paced and continually changing, in order to provide clients with the business intelligence they need, our own service and analysis is continually evolving. We remain client and industry focused, continually looking at ways to provide new, innovative analysis. Datamonitor Healthcare is made up of a great team. I think every single person in the team and across the wider Informa BI Pharma division is focused in this same way.
Why do you think our customers like Datamonitor Healthcare?
As I said earlier, we are constantly evolving and we’re always looking to improve the service and provide clients with what they need. I think one of our other key attributes, is that we’re very transparent with our methodologies. We want to provide as much information about the analysis as possible, but also how we’ve come to those conclusions. We’re very transparent with all the assumptions that have gone into our company sales-based and patient-based forecasts. I think it is important for clients to understand all the steps, sources, and processes that have been used to form a forecast; often this can be as valuable as the forecast itself.
What do you think your greatest achievement has been since working at Datamonitor Healthcare?
I’ve done a lot of work with the interactive data analysis and this is something that we’ve been continually developing. I worked on the PharmAspect products and more recently the up and coming PVX 2.0 company analysis platform. We’ve really focused on providing analysis and tools to allow clients to explore the data and answer the important questions on the service. A lot of thought and time goes into the development of the interactive products and we are continuously looking at ways to add new innovative analysis and data to enhance our content.
What are you most excited about this year in the pharmaceutical market?
Last year we saw a lot of M&A activity with a number of big deals complete, but also some that never came to fruition. I think it’s going to continue this year, we’ve already seem Pfizer’s announcement that it will acquire Hospira, so I do think there’s more to come. I think it’s a sign that pharma companies are having to change their strategies and how they approach the industry.
From a more therapeutic angle, the oncology immunotherapies market has seen a lot of activity and is an exciting area. There are a number of different late-stage PD-1 drugs being developed by multiple big pharma companies. They’ve started gaining approvals in smaller indications such as melanoma, but the key commercial targets for these drugs is the lucrative indications such as NSCLC. It will be interesting to see how they evolve in terms of clinical effectiveness, but also how they actually compete with each other as there are so many big companies trying to gain entry into this competitive area.
Outside work, what do you enjoy doing?
I’m very active so I do a lot of sport. I’ve sailed since I was five and competed at an international level so I still do quite a lot of sailing. I was based in the Mediterranean for six months as part of a professional racing team so that was pretty good.
A big thank you to James for taking the time to talk to us!
- If you’d like to keep up to date with what James is up to this year you can follow him on twitter by clicking here.
- You can also read his full bio here.